Xinteza API Overview
Xinteza is developing advanced proprietary biosynthesis and bioextraction technologies related to the production of cannabinoid-based active pharmaceutical ingredients (APIs) for the pharmaceutical and food industries. The company is engaged in the research and discovery of a wide array of new genes and ultra-novel genetic paths for the biosynthesis of cannabinoids and psychoactive ingredients and the development of their bioproduction methods. Xinteza holds the exclusive license for both cannabinoids and psychoactives from the Weizmann Institute and is building an exceptional portfolio of dozens of related IP and patents.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Xinteza Introduces True Water-Soluble Cannabinoids Biosynthesis to Revolutionize Beverages, Cosmetics, and Pharma
Xinteza API Ltd. has announced a breakthrough discovery of glycosylated cannabinoid genes and enzymes, which expands their novel biosynthesis platform. The discovery was made by Prof. Asaph Aharoni at the Weizmann Institute of Science. The newly found sub-set of enzymes and genes enables the production of true water-soluble cannabinoids, eliminating the need for liposomes or other nanoparticles. This discovery has a growth-positive impact on Xinteza API Ltd. as it offers a cleaner and more sustainable alternative to oil-based cannabinoid products. Xinteza API Ltd. is currently engaged in collaboration discussions with partners to turn this discovery into reality. The company operates in collaboration with the Weizmann Institute of Science and has an exclusive license for cannabinoids and psychedelics from the institute.
Partners
growth-positive
Xinteza Introduces Novel Key Enzyme to Solve Major Bottlenecks in Cannabinoid Biosynthesis
Xinteza API Ltd. has announced the discovery of a new catalytic enzyme that improves cannabinoid biosynthesis production systems. The enzyme, called PT-X, offers improved catalytic activity and compatibility for introduction into micro-organism-based cannabinoid biosynthesis industrial production systems. Xinteza is collaborating with the Weizmann Institute of Science and is operating under a license from Yeda, the commercial arm of the institute. The discovery of the enzyme is expected to significantly improve the cost to efficacy ratio of current cannabinoid biosynthesis production. Xinteza aims to revolutionize the commercial-scale synthesis of cannabinoids and psychedelics by implementing its disruptive discoveries of novel genes and genetic pathways.
PartnersInvestment
growth-positive
IM Cannabis Expands Innovation Portfolio with Investment in Xinteza to Develop Innovative Biosynthesis Technology based on Weizmann Institute Research
IM Cannabis Corp. has announced its investment in biosynthesis technology developed by Xinteza API Ltd. The company will acquire 25% of Xintezas outstanding common shares for up to US$1.7 million. IMCs investment will be funded with existing cash resources. Xinteza, under an exclusive license from Yeda Research & Development Company Ltd., is developing proprietary technologies for the production of cannabinoid-based active pharmaceutical ingredients (API) using biosynthesis and bio-extraction technologies. IMCs investment aligns with its strategy to develop cannabis-based medicine and medical devices for both local and international markets. The investment is expected to yield a low-cost and scalable method of producing cannabinoids, supporting the growing pharmaceutical applications and derivative product formats worldwide.
Investment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Seed |
| Rounds | 1 |
| Investors | 0 |
Team Members
3
Employees: 1-10
Web & Social Links
| Website | xinteza.com |
Locations
Tel Aviv, Israel
Photos & Videos
No files yet
